ACUTE myeloid leukemiaANTIFUNGAL agentsPHARMACOKINETICSDRUG monitoringLEUCOCYTESBackground: Acute myeloid leukemia (AML) is a life-threatening disease whose treatment is made difficult by a number of mutations or receptor overexpression in the proliferating cellular clones. Life expectancy of pati...
Mylotarg is used to treat a certain type (CD33-positive) of newly-diagnosed acute myeloid leukemia in adults and children at least 1 month old.Mylotarg is also used to treat CD33-positive acute myeloid leukemia after other treatments did not work or have stopped working in adults and children...
Acute promyelocytic leukemia is a common malignant disease of hematopoietic tissue. T (15, 17) chromosome rearrangements lead to this malignant tumor. APL is characterized by representative promyelocytic leukemia protein/retinoic acid receptor a gene fusion and high invasiveness and infiltration in clinical...
This is especially true for acute myeloid leukemia patients whose front-line treatment is generally a combination of an anthracyclin and the nucleoside analog Ara-C. Here, we show that a role of these drugs is the inhibition of the SUMO pathway. They induce a progressive loss of conjugation ...
Considering taking medication to treat acute myeloid leukemia with myelodysplasia related changes? Below is a list of common medications used to treat or reduce the symptoms of acute myeloid leukemia with myelodysplasia related changes. Follow the links to read common uses, side effects, dosage detai...
Rydapt is used together with other cancer medicines to treat acute myeloid leukemia.Rydapt is also used to treat certain rare blood disorders, including systemic mastocytosis with mast cell leukemia or other cancers affecting the blood, bone marrow, or lymphatic tissue....
We found that all examples of nonrandomized clinical trials being used to confirm benefit were for drugs to treat leukemia (3 indications for imatinib and 1 each for ponatinib, nilotinib, and omacetaxine). Updates on Ongoing Postapproval Evaluations The FDA reported that postapproval evaluations for...
Drugs introduced over the past 25 years have benefitted many patients with acute myeloid leukemia (AML) and provided cure for some. Still, AML remains difficult to treat, and most patients will eventually die from their disease. Therefore, novel drugs and drug combinations are under intense inves...
In June, HYML-122, a drug targeting acute myeloid leukemia, was approved by the SDA for a clinical trial. It was developed by a research team from Hefei Institute of Physical Science. If the trial is successful, the drug will be put into clinical use in five years. ...
Venetoclax (brand nameVenclexta) may be used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults, or newly diagnosed acute myeloid leukemia (AML) in those aged 75 years or older, or with other conditions that prevent intensive chemotherapy. For AML, veneto...